Lyra Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 62.68 million compared to USD 55.28 million a year ago. Basic loss per share from continuing operations was USD 1.26 compared to USD 1.83 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.291 USD | -0.34% |
|
+6.99% | -94.45% |
Jul. 01 | Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Small Cap Completeness Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-94.45% | 17.74M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- LYRA Stock
- News Lyra Therapeutics, Inc.
- Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023